Impilo invests in Decon – a leading mobility player within power-assisted electrical wheelchair solutions
Impilo has acquired a majority position in Decon Wheel AB (“Decon”), a developer and producer of high-quality power assist electrical solutions for manual wheelchairs, from its founders, who will continue as minority owners. In parallel with Impilo’s investment into Decon, Decon will acquire its long-term partner, Mobility Products, in the Netherlands.
Decon was founded in 1989 in Hyltebruk, Sweden, and employs c. 40 employees with 2022 sales of SEK 124m. Decon develops, assemblies, and distributes high-quality power-assisted electrical solutions for wheelchairs. With a user-centric development process, Decon’s solutions enable an active life for people with disabilities and thus “create freedom” in their day-to-day life. The company has its assembly facility in Hyltebruk, and from there, they serve a distributor network across +25 countries.
Read moreNews
KKR and Impilo announce strategic partnership together with management in rare disease platform Immedica Pharma
Stockholm and London, 23 April 2024 – Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.
Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform
Impilo has closed its investment in Avia Pharma Holding AB, a Sweden-based OTC and Rx pharmaceutical company with presence in the Nordics and Germany. Impilo now partners with two of the co-founders and management of Avia. Our ambition is to build a leading Northern European OTC / Rx platform through organic and inorganic growth.
Loargys® (pegzilarginase) approved in the EU for treatment of arginase 1 deficiency (ARG1-D)
Immedica today announces that the European Commission has granted marketing authorization of Loargys® (pegzilarginase) for the treatment of arginase 1 deficiency (ARG1-D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older. The approval follows the positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use on October 12.